Brexafemme is an antifungal drug owned by Scynexis. It contains the active ingredient ibrexafungerp citrate and was first approved for market use on June 1, 2021. The drug is available in oral tablet form and is patented with 5 drug patents, none of which have expired so far.
The generic version of Brexafemme can potentially be released after June 10, 2039. This date takes into account the expiration date of the last patent, held under the title 'Antifungal agents with enhanced activity in acidic pH', which expires on June 10, 2039. Drug patent challenges can be initiated against Brexafemme from June 1, 2030.
Brexafemme is used to treat adult and post-menarchal pediatric females affected with vulvovaginal candidiasis (VVC). The drug, which contains the active ingredient ibrexafungerp citrate, also helps reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in these individuals.
Brexafemme holds 5 patents, none of which have expired to date. The last patent, titled 'Antifungal agents with enhanced activity in acidic pH', expires on June 10, 2039. This determines the potential release date of the Brexafemme generic. Below are the details of the patent: